Cypher Impresses FDA Panel; Approval Recommended With More Drug Data
This article was originally published in The Gray Sheet
Executive Summary
The pharmacokinetic study specified by FDA's Circulatory System Devices Panel as a condition of approval for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent could become a standard requirement for future drug/device combination trials
You may also be interested in...
Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar
The FDA Circulatory System Devices Panel endorsed Boston Scientific's proposed ARRIVE 2,000-patient, five-year Taxus postmarket study with no additional conditions beyond proposals made by the company
Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar
The FDA Circulatory System Devices Panel endorsed Boston Scientific's proposed ARRIVE 2,000-patient, five-year Taxus postmarket study with no additional conditions beyond proposals made by the company
Guidant ICD, Stent Tactics Assuage Wall Street; Q1 Index Inches Up
Guidant allayed investor uncertainty over its future business strategy by winning a favorable MCAC reimbursement recommendation and executing a string of stent technology acquisitions, propelling the stock ahead 17.3% for the first quarter